ArticleJournal of advanced research2026
Fucose-tobramycin sponge-like microparticles to treat pulmonary Pseudomonas aeruginosa infections in a lectin-competitive approach.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe high incidence of pulmonary infections caused by multidrug-resistant bacteria such as Pseudomonas aeruginosa (PA) poses significant treatment challenges. Dry powder inhaler (DPIs) are an effective treatment method, delivering antibiotics directly to lung lesions. However, DPIs face two main issues: abnormal respiratory variability causes inadequate pulmonary deposition and PA's biofilms hinder antibiotic access.
objectivesA sponge-like dry powder based on the lectin-competitive strategy was developed with tobramycin (TOB) to solve the crucial issue.
methodsLectin-affinity sugars were screened using isothermal titration calorimetry. Sponge-like TOB-Formulation were then developed with the selected sugar as a carrier via spray freeze-drying. The formulation with the highest lung delivery efficiency was identified with a next-generation impactor and validated in a rat model of chronic pulmonary infection.
resultsFucose was used as a carrier to develop sponge-like TOB- Formulation by spray freeze-drying technology with spherical low-density and nanoporous particles, making them suitable for patient's inspiratory mode and improving lung deposition. Among them, the F
conclusionThis tobramycin spongy-like dry powder, identified as high lectin affinity and excellent respiratory variability tolerance, holds significant promise for the treatment of pulmonary infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.